The label expansion was supported by two Phase III trialsa 12-week induction study and a 52-week maintenance studyboth of which met the primary endpoint of clinical remission
Neither medication is universally 'better'response depends on your unique genetic and metabolic profile
Before starting retatrutide (within a trial setting), your clinician should: Conduct a thorough medical history review , including assessment of conditions that may be trial exclusion criteria or require particular caution for example, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
Recently, C9orf72-based ALS/FTLD rodent models have been generated [94], and it will be interesting to investigate whether alterations in glucose and cholesterol metabolism are associated, in these models, with disease severity
Because there are no needles or chemical agents involved, the risk of unnatural lumping or systemic chemical reactions is eliminated
Also, if you decide to take L-carnitine supplements, please consult your doctor first